乳房聚丙烯酰胺水凝胶取出术的手术配合

对81例患者行乳房内聚丙烯酰胺水凝胶（PAHG）取出术。结果手术均获成功，手术时间1．5～5．5h，平均2．6h。术中出血量90～1080ml，平均645．0ml。住院时间7～15d，平均8．9d。无血肿、感染等并发症，MRI复查PAHG清除率均达95．0％。提出术前加强心理护理并完善术前准备，术中密切监测生命体征和出入量，及时补充血容量，保证手术野照明，充分灌洗手术腔隙，减少PAHG在体内残留等措施是保证手术成功的重要环节。     

Design of a bifunctional fusion protein for ovarian cancer drug delivery: single-chain anti-CA125 core-streptavidin fusion protein.

We have developed a universal ovarian cancer cell targeting vehicle that can deliver biotinylated therapeutic drugs. A single-chain antibody variable domain (scFv) that recognizes the CA125 antigen of ovarian cancer cells was fused with a core-streptavidin domain (core-streptavidin-VL-VH and VL-VH-core-streptavidin orientations) using recombinant DNA technology and then expressed in Escherichia coli using the T7 expression system. The bifunctional fusion protein (bfFp) was expressed in a shaker flask culture, extracted from the periplasmic soluble protein, and affinity purified using an IMAC column. The two distinct activities (biotin binding and anti-CA125) of the bfFp were demonstrated using ELISA, Western blot and confocal laser-scanning microscopy (CLSM). The ELISA method utilized human NIH OVCAR-3 cells along with biotinylated bovine serum albumin (B-BSA) or biotinylated liposomes, whereas, the Western blot involved probing with B-BSA. The CLSM study has shown specificity in binding to the OVCAR-3 cell-line. ELISA and Western blot studies have confirmed the bifunctional activity and specificity. In the presence of bfFp, there was enhanced binding of biotinylated antigen and liposome to OVCAR-3 cells. In contrast, the control EMT6 cells, which do not express the CA125 antigen, showed minimal binding of the bfFp. Consequently, bfFp based targeting of biotinylated therapeutic drugs, proteins, liposomes, or nanoparticles could be an alternative, convenient method to deliver effective therapy to ovarian cancer patients. Peritoneal infusion of the bfFp-therapeutic complex could also be effective in locally targeting the most common site of metastatic spread.     

刺鼠信号蛋白对自体移植皮片中酪氨酸酶的活性影响

目的 检测刺鼠信号蛋白对自体移植皮片中酪氨酸酶的活性影响,进一步认识自体移植皮片过度色素沉着的原因。方法 建立过度色素沉着的自体移植皮片的动物模型；利用免疫组织化学方法分别检测刺鼠信号蛋白作用前后自体移植皮片中酪氨酸酶的表达,并与对照治疗组及正常皮肤相比较。结果 酪氨酸酶的表达定位于表皮基底部黑色素细胞的胞浆,在大部分组织中呈阳性表达,经刺鼠信号蛋白作用后酪氨酸酶在自体移植皮片中的表达明显减少,与在其他各对照组中的表达差异有极显著意义（P＜0.01）。结论 刺鼠信号蛋白在自体移植皮片中能竞争性拮抗α-MSH的黑色素合成,使皮片着色能力降低,从而证明皮片移植后表皮细胞中α-MSH的表达上调是皮片呈过度色素沉着的重要原因。     

中西医结合治疗小儿急性肾小球肾炎临床观察

急性肾小球肾炎为临床常见病，多发于少年儿童，男性多见。西医除对症处理外，无特效药物，中药治疗本病可明显缩短病程。笔者自2003年1月至2006年1月用清热利湿解毒汤治疗急性肾小球肾炎60例取得确切疗效，现报道如下。     

腹腔镜肝切除术患者的护理

笔者报道腹腔镜肝切除术患者的护理。术前进行心理护理和呼吸训练；术后注意早期活动，加强腹腔镜CO2气腹后的观察、护理，做好皮下气肿、胆漏、出血、高碳酸血症和下肢静脉血栓等术后并发症的观察及护理。认为周到细致的护理是手术成功的重要保证。     

Development and optimization of an indirect enzyme-linked immunosorbent assay for the determination of Hexoestrol

An indirect enzyme-linked immunosorbent assay (ELISA) for the detection of hexoestrol (HES) was developed, optimized and validated for the analysis of HES in pork. Many parameters, such as the volume ratio of solution A and solution B, colour developing time, pH value, incubation time, the volume ratio of the standard solution and diluted antiserum, blocking solution, blocking condition, coating solution and coating condition were studied and optimized in the paper. The regression equation of the final inhibition curve is y = - 0.3345x + 1.4955, R²=0.9913. The linear range is 0.1-8.1 ng/ml, and the IC₅₀ is 0.671 ng/ml. The specificity of the assay was evaluated by the cross-reactivity rates of six compounds, of which two structurally related compounds had a relatively higher cross-reactivity rate of 25% and 6%. HES was added into a pork sample at 5 ng/g level and then the sample was extracted. The recovery is between 49.6% and 79.2%, and the variation coefficient is 0.164.     

给药系统

近年来，伴随着药物治疗的快速发展．以药理活性非常强的药物为代表，开发出许多用药时必须给予足够关注的药物，“用药最适化”这一概念逐渐成为人们非常关注的问题。这主要是为了实现用药时的最佳形式。尽可能地根据选择或者需要控制药物的浓度．时间模式。输送到药物的作用表达部位。实现治疗用药的安全性。但是，历来的方法却很难实现这一点，通过利用新的技术和方法调控药物在体内的动态变化，以获得最好治疗效果为中心的药物使用方法和药剂正在开发之中。这就是给药系统，使用可以表达自身概念的语言来命名。虽然都是以各种药物在体内的动态过程作为调控对象，但是还分为①controlled release（调控释放给药）；②开发新的给药途径、克服药物吸收障碍；③靶向给药（targeting）等三个途径。